Related Experiment Video

Updated: Jun 3, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.0K

Wip1 phosphatase activator QGC-8-52 specifically sensitizes p53-negative cancer cells to chemotherapy while

Ke Wu1, Xiao-Xiao Ge2, Xiao-Fan Duan2

  • 1Division of Cancer Research and Training, Department of Internal Medicine, Charls Drew University of Medicine and Science, David Geffen UCLA School of Medicine and UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA; School of Nursing, Wuhan University, Wuhan, 430071, China.

Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy
|January 9, 2025
PubMed

Insights

Activating Wip1 phosphatase with QGC-8-52 sensitizes p53-deleted breast cancers to chemotherapy. This novel strategy boosts tumor apoptosis while protecting normal tissues, offering a safe therapeutic approach for specific cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Wip1 phosphatase is crucial in tissue homeostasis and disease pathogenesis, making it a cancer drug target.
  • Wip1 inhibition may be ineffective in p53-deficient cancers.
  • Novel strategies are needed to target Wip1 in specific cancer types.

Purpose of the Study:

  • To characterize the novel Wip1 phosphatase activator, QGC-8-52, in preclinical breast cancer models.
  • To investigate the mechanism of QGC-8-52 in sensitizing p53-deleted cancer cells to chemotherapy.
  • To evaluate the therapeutic potential of Wip1 activation in p53-deficient malignancies.

Main Methods:

  • Preclinical models of breast malignancies.
  • Assessment of QGC-8-52 activity and its effects on cancer cell lines.
  • Analysis of Wip1-FOXO3a interaction and FOXO3a dephosphorylation.
  • Evaluation of TRAIL gene transcription and apoptosis induction.

Main Results:

  • QGC-8-52 significantly sensitizes p53-deleted cancer cells to chemotherapeutic agents.
  • Wip1 activation enhances FOXO3a transcription of the proapoptotic TRAIL gene via dephosphorylation.
  • Activated Wip1 protects normal cells from chemotherapy-induced apoptosis.
  • The sensitizing effect is specific to p53-negative cancer cells.

Conclusions:

  • Wip1 activation by QGC-8-52 represents a potential therapeutic strategy for p53-deleted cancers.
  • This approach selectively enhances apoptosis in tumors while protecting normal tissues.
  • Targeting Wip1 offers a safe and effective treatment option for specific cancer types lacking p53.
Keywords:
Breast cancerDephosphorylationFOXO3aTRAILWip1

More Related Videos

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

10.9K
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

14.9K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.4K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.1K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K